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ABSTRACT
Liver injury is a common complication in allogeneic hematopoietic stem cell transplantation. Its major causes
comprise graft-versus-host disease (GVHD), infection, and toxicities of preparative regimens and immuno-
suppressants; however, we have little information on liver injuries after reduced intensity cord blood trans-
plantation (RICBT). We reviewed medical records of 104 recipients who underwent RICBT between March
2002 and May 2004 at Toranomon Hospital. Preparative regimen and GVHD prophylaxis comprised fludarabine/
melphalan/total body irradiation and cyclosporine or tacrolimus. We assessed the etiology of liver injuries based
on the clinical presentation, laboratory results, comorbid events, and imaging studies in 85 patients who
achieved primary engraftment. The severity of liver dysfunction was assessed according to the National Cancer
Institute Common Toxicity Criteria version 2.0. Hyperbilirubinemia was graded according to a report by
Hogan et al (Blood. 2004;103:78-84). Moderate to very severe liver injuries were observed in 36 patients. Their
causes included cholestatic liver disease (CLD) related to GVHD or sepsis (n 15), GVHD (n 7), cholangitis
lenta (n  5), and others (n  9). Median onsets of CLD, GVHD, and cholangitis lenta were days 37, 40, and
22, respectively. Frequencies of grade 3-4 alanine aminotransferase elevation were comparable across the 3
types of hepatic injuries. Serum -glutamil transpeptidase was not elevated in any patients with cholangitis
lenta, whereas 27% and 40% of patients with CLD and GVHD, respectively, developed grade 3-4 -glutamil
transpeptidase elevation. Multivariate analysis identified 2 risk factors for hyperbilirubinemia; grade II-IV
acute GVHD (relative risk, 2.23; 95% confidential interval, 1.11-4.47; P  .024) and blood stream infection
(relative risk, 3.77; 95% confidential interval, 1.91-7.44; P  .00013). In conclusion, the present study has
demonstrated that the hepatic injuries are significant problems after RICBT, and that GVHD and blood stream
infection contribute to their pathogenesis.
© 2006 American Society for Blood and Marrow Transplantation
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sNTRODUCTION
Liver injury is a common and sometimes fatal
omplication in allogeneic hematopoietic stem cell
ransplantation (allo-SCT). Its major causes comprise
eno-occlusive disease (VOD), graft-versus-host dis- 5
302ase (GVHD), infection, and adverse effects of pre-
arative regimens, immunosuppressants, and antibiot-
cs [1]. In the era of myeloablative conditioning,
ntensive chemoradiotherapy injured hepatic sinu-
oids, causing VOD with a high incidence of 21%-
4% [2-6]. After the introduction of reduced intensity
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Hepatic Injury after RIBCT 1303tem cell transplantation (RIST), the incidence of
OD decreased to 0%-17% [7-9]. The incidence of
VHD after RIST is comparable to that after con-
entional allo-SCT [10,11], whereas patients who un-
ergo RIST, who are usually older and/or have co-
orbid factors, frequently develop infectious diseases
r drug-induced liver injuries [12,13]. The reported
ncidence of liver injury after RIST was almost same
s that after myeloablative allo-SCT [7].
Cord blood (CB) is an established stem cell source
n myeloablative transplantation [14-16]. The inci-
ence of GVHD after myeloablative CB-transplanta-
ion (CBT) is comparable to that of allo-SCT from a
atched unrelated donor [14,15]. Deaths related to
VHD are more common in allo-SCT from an un-
elated donor, whereas deaths related to toxicity in-
luding regimen-related toxicity and infections are
ore frequent in CBT [15]. It remains unknown
hether the high incidence of infection-related deaths
re associated with naive CB cells, disease aggressive-
ess, or patient conditions. Infectious diseases are fre-
uent and severe after CBT compared with allo-SCT
sing other stem cell sources [17-19]. These ﬁndings
uggest that immune recovery is delayed after CBT
20]. Moreover, owing to the development of univer-
al stem cell source and reduced intensity condition-
ng regimen [21,22], increasing numbers of elderly
atients are being treated with CBT. Elderly patients
an beneﬁt from this curative treatment procedure;
owever, elderly patients might be easily affected
y infectious diseases or other toxicities. As a result,
onrelapse mortality after reduced intensity CBT
RICBT) is high. We have little information on trans-
lant-related toxicity after RICBT [21-23]. We un-
erwent retrospective study to clarify the incidence
nd clinical features of liver injuries after RICBT.
ETHODS
ata Collection
We reviewed medical records of 104 recipients who
nderwent RICBT between March 2002 and May 2004
t Toranomon Hospital (Tokyo, Japan). Their charac-
eristics are listed in Table 1. Ninety-one of the 104
atients had high-risk disease including acute myeloid
eukemia in relapse or advanced (2) complete remis-
ion (CR; n  31), acute lymphoid leukemia other than
rst CR (n  8), chronic myeloid leukemia in blastic
hase (n 1), myelodysplasia other than refractory ane-
ia (n  8), myeloma in any disease status (n  4),
efractory lymphoma (n  38, all with lymphoma), and
diopathic myeloﬁbrosis (n  1).
ransplantation Procedures and Supportive Care
A CB unit was searched through the Japan Cord
lood Bank Network [24]. CB units that were avail- 2ble for CBT were at least 4/6 serologically HLA-
ntigen matched, and contained 2  10E7 nucle-
ted cells/kg of recipient body weight before
reezing. All provided CB units were negative for
ytomegalovirus-speciﬁc immunoglobulin M and G
ntibodies.
Transplantation procedures are presented in Ta-
le 1. All patients received purine analog-based pre-
arative regimens. Granulocyte colony-stimulating
actor (G-CSF) was administered from day 1 until
eutrophil engraftment. GVHD prophylaxis con-
isted of tacrolimus 0.03 mg/kg or cyclosporine 3
g/kg in a continuous infusion starting on day 1.
rough blood levels of these drugs were monitored
-3 times a week and dosages were modiﬁed to main-
ain target levels of 10-15 ng/mL for tacrolimus and
able 1. Patients’ Characteristics and Transplantation Procedures
atient characteristics
Age (y), median (range) 57 (18-79)
Male/female 61/43
rimary diseases
AML/MDS 44
Malignant lymphoma 38
Acute lymphoblastic leukemia 12
Severe aplastic anemia 4
Chronic myeloid leukemia 1
Multiple myeloma 4
Idiopathic myelofibrosis 1
isk of underlying diseases*
High/low 91/13
iver status
Positive HBs antigen 4
Positive HCV antibody 3
AST/ALT > ULN 30/24
ALP/GTP > ULN 77/20
bilirubin >1.2 mg/dL 32
ransplantation procedures
Conditioning regimen
Flu  Mel  TBI 4 Gy/8 Gy 97/2
Flu  BU  TBI 4 Gy/8 Gy 1/4
GVHD prophylaxis
Cyclosporine/tacrolimus 79/25
Infused nucleated cells  107/kg,
median (range) 2.8 (2.0-4.6)
HLA disparity (antigen), 2/1/0 88/15/1
ransplantation outcomes†
Documented blood stream infection 26 (31%)
CMV disease/antigenemia 15 (18%)/50 (59%)
ML indicates acute myeloid leukemia; MDS, myelodysplastic syn-
dromes; ULN, upper limit of normal; Flu, ﬂudarabine; Mel,
melphalan; Bu, busulfan; TBI, total body irradiation.
We divided the risk of transplantation into 2 groups. The low-risk
group was characterized as follows: acute myeloid or lymphoid
leukemia in ﬁrst and second remission, chronic myelogeneous
leukemia in chronia phase, and myelodysplastic syndrome re-
fractory anemia. The other patients were deﬁned as having
high-risk diseases.
Percentage was calculated based on 85 patients who achieved
primary engraftment.00-400 ng/mL for cyclosporine [25-28].
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E. Kusumi et al1304Primary engraftment was deﬁned by an absolute
eutrophil count of 0.5  10E9/L for 3 consecutive
ays.
The diagnosis of GVHDwas made based on clinical
udgments and results of skin or gut biopsy. Acute
VHD was graded according to consensus criteria [29].
hen patients developed grade II-IV acute GVHD, we
nitiated 1-2 mg/kg per day of methylprednisolone in
ddition to tacrolimus or cyclosporine.
Patients were managed in reverse isolation in lam-
nar airﬂow-equipped rooms. All patients received to-
uﬂoxacin 450 mg/d from the start of conditioning
ntil neutrophil engraftment. Fluconazole 200 mg/d
r micafungin 150 mg/d and acyclovir 600 mg/d were
iven from the start of conditioning until cessation of
VHD prophylaxis. They received prophylaxis with
rimethoprim-sulfamethoxazole against Pneumocystis
irovecii infection from the start of conditioning until
essation of immunosuppressants or disappearance of
hronic GVHD. When patients develop neutropenic
ever, tosuﬂoxacin was changed to broad-spectrum
ntibiotics [30]. Because most patients had been
reated severely and received multiple transfusions be-
ore transplantation, anticytomegalovirus (CMV) an-
ibodies were not examined before transplantation. All
atients were monitored for CMV pp65 antigenemia
nce a week. When CMV antigenemia exceeded 10/
0,000, patients preemptively received foscarnet 30
g/kg intravenously twice daily.
ssessment of Liver Dysfunction
Before transplantation, patients were evaluated for
he presence of liver dysfunction by history, physical
xamination, and laboratory tests (aspartate amino-
ransferase [AST], alanine aminotransferase [ALT],
lkaline phosphatase [ALP], -glutamil transpeptidase
GTP], bilirubin, albumin, prothrombin time, and
ests for hepatitis B virus [HBV] and hepatitis C virus
HCV]). Patients with symptoms, signs, or laboratory
ndings of liver dysfunction were evaluated by addi-
ional laboratory tests, liver imaging, and consultation
o hepatologists as clinically indicated.
iagnostic Criteria
Severity of liver dysfunction was assessed accord-
ng to the National Cancer Institute Common Tox-
city Criteria version 2.0. Hyperbilirubinemia was
raded according to the report by Hogan et al [7];
eak serum levels of total bilirubin 1.2-3.9, 4.0-6.9,
.0-9.9, and 10.0 mg/dL were classiﬁed as mild,
oderate, severe, and very severe liver dysfunction,
espectively.
Attribution of causes of liver dysfunction were
etermined by a hepatologist (KR), a hematologist
KE), and a pathologist (SK) based on clinical presen-
ation, laboratory results, comorbid events, liver im- 6ging studies, and histology. When there was dis-
greement in the diagnosis of liver dysfunction among
he 3 researchers, we made a ﬁnal diagnosis after
iscussion.
VOD was diagnosed according to criteria of Mc-
onald et al [2]. In allograft recipients with skin or gut
VHD, cholestatic liver abnormalities are usually at-
ributable to liver GVHD [1]. We made a diagnosis of
iver GVHD when patients with skin or gut GVHD
eveloped jaundice. Cholangitis lenta was clinically
iagnosed when patients with sepsis developed jaun-
ice [1]. Cholangitis lenta frequently occurs in pa-
ients with active GVHD, and these 2 factors appear
odependent. When patients with active GVHD and
epsis develop jaundice, it is difﬁcult to differentiate
etween liver GVHD and cholangitis lenta. A diag-
osis of “cholestatic liver disease related to GVHD
r sepsis (CLD)” was given to these patients [1].
atients who developed liver dysfunction without
vidence of GVHD and/or sepsis were assessed for
ther causes of liver dysfunction such as drug-in-
uced liver dysfunction, ischemia, or others. A pri-
ary cause of each patient’s liver dysfunction was
dentiﬁed, followed by additional causes supported
y evidence when liver dysfunction was thought to
e multifactorial.
ndpoints and Statistical Analysis
This study investigated the clinical features of liver
ysfunction and identiﬁed risk factors for hyperbiliru-
inemia among patients who achieved engraftment
fter RICBT. The cumulative incidence of the eleva-
ion of serum total bilirubin level was evaluated using
he Gray method [31], considering death without total
ilirubin elevation as a competing risk. Potential con-
ounding factors considered in the analysis were age,
ex, disease status, AST levels, ALT levels, ALP levels,
TP levels, total bilirubin levels, HCV antibody,
umber of HLA mismatches, stem cell dose, GVHD
rophylactic agent, CMV antigenemia, grade II-IV
cute GVHD, and blood stream infection. Propor-
ional hazard modeling was used to evaluate the inﬂu-
nce of these factors on the incidence of total bilirubin
levation by using proportional hazard modeling and
reating the development of acute GVHD, positive
MV antigenemia, and bacteremia as time-dependent
ovariates. Factors associated with at least borderline
igniﬁcance (P  .10) in univariate analyses were sub-
ected to a multivariate analysis using backward step-
ise proportional hazard modeling. P values 0.05
ere considered statistically signiﬁcant. Survival was
stimated by the Kaplan-Meier method. Median fol-
ow-up of surviving patients was 251 days (range,
2-873 days).
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Hepatic Injury after RIBCT 1305ESULTS
linical Outcomes after RICBT
Eighty-ﬁve (82%) patients achieved primary en-
raftment at a median of 20 days (range, 9-89 days).
he other 19 patients died before engraftment; 17
atients died of sepsis, 1 patient died of probable
nvasive pulmonary aspergillosis, and the other patient
ied of progression of primary disease. Seven patients
ied after day 28; however, they developed sepsis
uring severe neutropenia soon after transplanta-
ion. Of the 85 patients who achieved engraftment,
1 and 27 patients developed grade II-IV and III-IV
cute GVHD, respectively. The median onset of
rade II-IV acute GVHD was day 28 (range, 11-92).
ifteen of 37 patients (41%) who survived 100 days
ithout disease progression developed chronic
VHD. Estimated 1-year overall survival was 36%
95% conﬁdential interval ([CI], 26%-46%). Causes
f deaths were nonrelapse mortality in 56 patients and
isease progression in 6 patients. The primary cause
as infection in 41 of 56 patients who died without
isease progression.
athogens of Blood Stream Infections
Causative organisms of bloodstream infections,
hich is diagnosed when patient had a recognized
athogen cultured from 1 blood culture, and the
rganism cultured from blood was unrelated to any
nfection at another site, and their outcomes in 26
atients were S epidermidis (n  6, 3 fatal), P aerugi-
igure 1. Cumulative incidences of total bilirubin elevation (4.0 mg/
L; black line) and death without total bilirubin elevation (gray line).
able 2. Clinical Features for Three Representative Causes of Liver Dy
Median Onset
(range)
Mortality
Rate
holestatic liver disease related
to GVHD or sepsis 37 (17-111) 93%
holangitis lenta 22 (6-32) 80%
VHD 40 (22-86) 67% 17osa (n  5, 4 fatal), E faecalis (n  4, 3 fatal), M
uberculosis (n  3, 2 fatal), MRSA (n  2, 1 fatal), S
altophilia (n  1, 1 fatal), S mitis (n  1, 1 fatal),
ram-positive rod (n  1, 1 fatal), E faecalis and S
pidermidis (n  1, 0 fatal), A hydrophilia (n  1, 0
atal), and S sanguis and E faecalis (n  1, 0 fatal).
hree patients with military tuberculosis received an-
ituberculosis therapy including ethambutol, isonia-
id, and rifampicin with or without pyrazinamide [19].
ncidence of Liver Injury
Hyperbilirubinemia was documented in 74 pa-
ients (87%; 95% CI, 83%-91%; mild n  38, mod-
rate n  11, severe n  7, and very severe n  18;
igure 1). Increased AST, ALT, ALP, and GTP levels
orresponding to grade 3-4 toxicities were observed in
9, 16, 35, and 13 patients, respectively.
linical Features of Hyperbilirubinemia
Causes of moderate to very severe hyperbiliru-
inemia included GVHD (n  7), cholangitis lenta
n 5), CLD (n 15), thrombotic thrombocytopenia
n  2), progression of primary disease (n  1), ome-
razole (n  1), cyclosporine (n  1), hemolysis (n 
), and multifactorial (n  4; liver congestion due to
eart failure and cholangitis lenta, rifampicin and
VHD, cefozopran and GVHD, rifampicin and cho-
estasis related to GVHD, or sepsis). No patient met
iagnostic criteria for VOD.
Clinical features of hyperbilirubinemia according
o their etiologies are listed in Table 2. Median onsets
f hyperbilirubinemia for GVHD, cholangitis lenta,
nd CLD were day 40 (range, 22-86 days), day 22
range, 6-32 days), and day 37 (range, 17-111 days),
espectively. Cholangitis lenta developed soon after
ransplantation compared with GVHD, and higher
erum GTP levels were not documented in patients
ith cholangitis lenta. Patients with GVHD tended to
ave better prognosis compared with those with
hlangitis lenta or CLD.
istopathologic Finding
Of the 36 patients with moderate to very severe
aundice, 7 had liver histology (Table 3). Bile duct
nﬂammation and cholestasis were observed in 6 and 5
atients, respectively. These ﬁndings were not ob-
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E. Kusumi et al1306erved in a patient with thrombotic thrombocytopenic
urpura (TTP). A patient with rifampicin-induced
epatotoxicity showed intrahepatocyte cholestasis.
isk Factor for Development of Hyperbilirubinemia
Results of univariate and multivariate analyses are
resented in Table 4. Grade II-IV acute GVHD (rel-
tive risk, 2.23; 95% CI, 1.11%-4.47%; P  .024) and
lood stream infection (relative risk, 3.77; 95% CI,
.91%-7.44%; P  .00013) were signiﬁcant risk fac-
ors on multivariate analysis.
ISCUSSION
Liver injury is a signiﬁcant complication after
ICBT. Moderate to very severe liver injuries were
iagnosed in 36 of the 85 patients who underwent
ICBT (42%; 95% CI, 37%-47%) in the present
tudy. No study has been reported on liver injuries
fter RICBT, although approximately 30% of patients
ho undergo RIST using peripheral blood stem cells
evelop moderate to very severe liver injuries [7,32].
he present study suggests that liver injuries are more
requent in RICBT than in RIST using peripheral
lood stem cells.
Liver injuries after allo-SCT can be classiﬁed into
categories; CLD, cholangitis lenta, and GVHD [7].
s presented in Table 2, CLD and GVHD presented
imilar clinical features, which were characterized by
he late onset and elevation of serum GTP. Because
LD has a higher mortality rate than GVHD, it is
easonable to assume that GVHD might underlie the
athogenesis of CLD, and it is frequently complicated
ith infections in CLD. In contrast, cholangitis lenta
eveloped during neutropenia after RICBT, and se-
um levels of GTP were not elevated in any of the 5
atients. The pathogenesis of cholangitis lenta might
iffer from that of GVHD and CLD.
Concerning pathologic examination, all patients
ith CLD or GVHD showed some evidence of bile
uct inﬂammation. Cholestasis was documented in all
ut 1 patient with CLD or GVHD. These ﬁndings
upport our hypothesis that GVHD might underlie
he pathogenesis of CLD. Interestingly, neither endo-
helial degradation nor thrombotic lesions were doc-
mented in a patient with TTP. These ﬁndings were
ompatible with our previous report that formation of
hrombotic lesions is not essential for the pathogene-
is of TTP after transplantation [33]. A patient with a
linical diagnosis of rifampicin-induced liver injury
howed pathologic evidence of intrahepatocyte cho-
estasis. These cases have demonstrated that patho-
ogic examination is useful in making a diagnosis of
iver injuries after RICBT.
Interestingly, GVHD and blood stream infection
were identiﬁed as risk factors of hyperbilirubinemiaTa U
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Hepatic Injury after RIBCT 1307fter RICBT. Because GVHD is frequently compli-
ated by infections, it is difﬁcult to distinguish effects
f GVHD from those of infections on the develop-
ent of liver injuries after allo-SCT [7]. It remains
nknown whether infections per se cause liver injury
fter transplantation; however, the present study has
emonstrated that the effect of blood stream infection
s more signiﬁcant than that of GVHD in the devel-
pment of hyperbilirubinemia after RICBT. Although
urther investigations are warranted to clarify the ex-
ct mechanism of hyperbilirubinemia attributable to
lood stream infection, we should recognize that jaun-
ice of unknown etiology might be caused by occult
lood stream infections in patients after RICBT. Flu-
arabine is a risk factor for liver dysfunction after
onmyeloablative allo-SCT [7]. We could not inves-
igate this possibility, because all patients received a
udarabine-containing conditioning regimen. Cyclo-
porine causes hyperbilirubinemia in dose-related
anner [34]. The diagnosis of cyclosporine-induced
yperbilirubinemia is always presumptive because it is
ased on a logistic approach rather than on absolute
riteria and speciﬁc diagnostic tests [1]. Only 1 patient
eveloped cyclosporine-induced hyperbilirubinemia,
o we did not include cyclosporine in the analysis of
isk factors for hyperbilirubinemia.
Estimated overall survival of 36% at 1 year is
omparable to that of previous reports [35] when con-
idering that most of patients had refractory or ad-
anced diseases. Because infection-related mortality
ithin 100 days is high in CBT compared with unre-
ated bone marrow transplantation, reduction of in-
able 4. Risk Factors for Incidence of Hyperbilirubinemia
nivariate analysis
Pretransplantation factors
Age
Sex
Disease status
AST elevation
ALT elevation
ALP elevation
GTP elevation
Total bilirubin elevation
HCV antibody
Number of HLA mismatches
Stem cell dose
GVHD prophylaxis
Post-transplantation factors (time-dependent covariates)
CMV antigenemia
Grade II-IV acute GVHD
Blood stream infection
ultivariate analysis
Grade II-IV acute GVHD
Blood stream infectiorection-related mortality would lead to increased sur- cival rates. Early infection-related mortality among
atients after CBT might be attributable to neutrope-
ia, disease status, and physiologic conditions of pa-
ients after RICBT [14].
Regimen-related mortality was not documented in
he present study. This ﬁnding suggests that RICBT is
feasible treatment option for elderly patients with
ematologic malignancies. Main causes of nonrelapse
ortalities were bacterial infections in this study, and
ost developed during neutropenia after reduced inten-
ity conditioning: thus, shortening of neutropenia might
ead to increased survival. Some researchers have re-
orted the usefulness of CBT using nonmyeloablative
onditioning or double-cord transplantation [36-38].
urther investigation of transplantation procedures is
arranted to improve survival of patients after RICBT.
atient selection is also important in RICBT to avoid
nfection-related mortalities. Because the mortality rate
fter blood stream infection is high [23], patients who are
t high risk for developing blood stream infection should
void RICBT [24,35]. A large-scale study is warranted to
lucidate the pretransplantation risk factors for develop-
ng blood stream infection.
This study provides important information on
iver injuries after RICBT; however, there are some
imitations to be discussed. First, this was a small
etrospective study, and unrecognized bias might have
nﬂuenced its results. Large-scale prospective studies
re required to clarify clinical features of hepatic in-
uries after RICBT. Second, none of the 5 patients
ith cholangitis lenta underwent autopsy or biopsy.
e have little information on histopathology of
Relative
Risk (95% CI) P
1.02 (0.99-1.04) .20
1.56 (0.80-3.04) .20
1.52 (0.59-3.94) .39
1.48 (0.77-2.86) .24
1.90 (0.97-3.70) .062
0.90 (0.42-1.91) .78
0.77 (0.26-2.23) .63
1.67 (0.82-3.37) .16
0.94 (0.13-6.66) .95
1.35 (0.49-3.69) .56
1.25 (0.70-2.24) .46
0.49 (0.20-1.17) .11
1.36 (0.61-3.00) .45
2.95 (1.47-5.90) .0023
4.49 (2.31-8.73) 9.4  106
2.23 (1.11-4.47) .024
3.77 (1.91-7.44) .00013holangitis lenta after RICBT. Third, viral hepatitis is
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E. Kusumi et al1308frequent cause of liver injuries after transplantation,
ut viral infections other than HBV, HCV, and CMV
ere not examined in this study. Occult viral infection
ight have injured the liver in patients after RICBT.
ourth, total parenteral nutrition (TPN) might have
aused liver injury. Because some patients were trans-
erred back to their referral hospital in the present
tudy, data regarding the incidence and duration of
PN were not available. Future studies on TPN-
nduced liver injuries after RICBT are warranted.
In conclusion, the present study has demon-
trated that hepatic injury is a signiﬁcant problem
fter RICBT, and that 2 factors, GVHD and blood
tream infection, contribute to its pathogenesis.
ptimal diagnostic and treatment strategies of
lood stream infection and proper management of
cute GVHD are warranted to decrease hepatic
amage after RICBT.
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